Transfusion-Associated Graft-Versus-Host Disease Risk and Transfusion Requirements After Cladribine in Multiple Sclerosis: Time to Revise Irradiation Policy?

Authors

Klaus Schmierer, Frederick Chen, David Paling

Published in

European journal of neurology. Volume 33. Issue 7. Pages e70698.

Abstract

Irradiation of cellular blood components prevents transfusion-associated graft-versus-host disease (TA-GVHD). UK and Spanish guidance recommend lifelong irradiation for all patients treated with purine analogues, including cladribine, irrespective of indication or dose.
To assess whether this approach is justified for people with multiple sclerosis (pwMS) receiving cladribine.
Narrative synthesis of immunological data, hemovigilance evidence, and national European transfusion guidelines.
Cladribine used in pwMS induces transient lymphopenia with modest, reversible T-cell effects and preserved vaccine responsiveness. Since introduction of universal pre-storage leucocyte depletion, hemovigilance data show no reported cases of TA-GVHD in this setting. European guidance is heterogeneous, ranging from indefinite to time-limited or unspecified durations.
Current evidence does not clearly support the need for lifelong irradiation after cladribine treatment in pwMS. Time-limited or individualized approaches merit consideration.

PMID:
42405441
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.